Hospital Injectable Products · LP-177
Benzathine benzylpenicillin Powder for injection
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-177Hospital Injectable Products
- Generic identity
- Benzathine benzylpenicillinPowder for injection
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-177
- Generic ingredient
- Benzathine benzylpenicillin
- Dosage form
- Powder for injection
- Proposed strength
- 1.2 million IU vial; 2.4 million IU vial
- Proposed pack
- Vial; carton 10 vials
- Portfolio category
- Hospital Injectable Products
About Benzathine benzylpenicillin
Benzathine benzylpenicillin, also called penicillin G benzathine, is a long-acting penicillin preparation. The benzathine form produces a depot effect and differs substantially from other injectable penicillin salts. It is used for selected susceptible infections or prevention programmes under specific guidance. The name penicillin alone is not sufficient for product selection because the salt and release characteristics determine the clinical presentation.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Examples of relevant clinical contexts include certain treponemal infections and prevention of recurrent rheumatic fever under applicable guidance. The diagnosis and exact protocol determine whether this depot formulation is appropriate. It is not a substitute for aqueous penicillin in every infection. The record lists powder-for-injection vials, while external references may describe a ready-made suspension; preparation and stability information cannot be transferred between them.
Important safety considerations
Penicillin allergy can lead to anaphylaxis and other serious reactions. Benzathine penicillin must never be given intravenously; incorrect vascular administration can be fatal. Severe local injury is another concern with improper injection. Treatment of certain infections can provoke an inflammatory reaction that requires clinical recognition. Assess prior beta-lactam reactions, patient factors and the capacity to manage an acute allergy. This is a professional-use depot medicine.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The source specifies powder with activity expressed in international units. The reconstitution requirements, resulting suspension, appropriate administration route and supply of any diluent must be confirmed for that exact vial. Other benzylpenicillin salts are separate products.
Professional preparation must follow the authorized label and local aseptic procedures. Confirm the correct container, concentration, route and expiry before use. Storage, transport, dilution compatibility and any period after opening or reconstitution require product-specific evidence; this page does not establish them.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Confirm diagnosis, required penicillin salt, activity units, allergy history and the local protocol. Administration requires trained staff and readiness to manage severe reactions.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Benzathine benzylpenicillin
- Dosage form / presentation
- Powder for injection
- Catalogue strength
- 1.2 million IU vial; 2.4 million IU vial
- Catalogue pack
- Vial; carton 10 vials
- Portfolio category
- Hospital Injectable Products
Layer 02
Unresolved product-specific fields
- The catalogue describes benzathine benzylpenicillin as powder for injection at 1.2 million IU and 2.4 million IU per vial. Exact physical form after preparation, diluent, route and preparation instructions require controlled evidence.
- The cited external US reference is a prefilled suspension. Its presentation, storage and administration instructions must not be imported into this powder record.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- MedlinePlus: Penicillin G Benzathine Injection — external formulation contextgovernment-hosted medicine monograph
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Sterile product specification confirming exact active chemical form, concentration or vial content, container/fill, authorised route(s), excipients/preservatives and preparation/compatibility controls.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-177, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-177.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.